Risk Stratification of Outcomes Among Patients with Adult T-Cell Leukemia/Lymphoma Receiving Allogeneic Hematopoietic Cell Transplantation: A Retrospective Analysis of the JSHCT ATL Working Group  by Yoshimitsu, Makoto et al.
Figure 1. Cumulative incidences of (A) NRM and relapse (B) OS and DFS.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107 S89CMVstatuspredicted inferiorOS (HR2.32p¼0.02) andDFS (HR
2.22 p¼0.03). Low CD3 dose (HR 2.04 P¼0.05) predicted DFS.
We conclude that some MCL patients given non-
myeloablative allogeneic HCT may achieve long-term sur-
vival and come off IS, despite having relapsed or refractory
disease at the time of HCT. Future studies addressing
appropriate timing of allogeneic HCT versus non-HCT ther-
apies for patients with MCL are needed.Figure.86
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Introduction: Disease status at allogeneic hematopoietic cell
transplantation (HCT) is the most important prognostic fac-
tor in HCT for adult T cell leukemia/lymphoma (ATL), but
other factors also need to be considered, including relatively
older recipient ages, performance status (PS), and comor-
bidities. Several scoring systems, such as the HCT-comor-
bidity index (CI) and the modiﬁed European Group for Blood
& Marrow Transplantation (EBMT) risk score (mEBMT), are
available for predicting outcomes in HCT recipients; how-
ever, their prognostic relevance in ATL is not well deﬁned.
Materials and Methods: We retrospectively evaluated the
HCT-CI and mEBMT in 635 ATL patients registered to the
Japan Society for Hematopoietic Cell Transplantation (JSHCT)
TRUMP database from 2008 until 2012. We further devel-
oped a new prognostic index (PI) for ATL patients receiving
HCT (ATL-HCT-PI) using each factor from the HCT-CI and the
mEBMT, as well as other known risk factors.
Results: In multivariate analyses, higher HCT-CI was associ-
ated with inferior overall survival (OS) in the following
comparisons: HCT-CI 0 (n ¼ 407) vs. 1e3 (n ¼ 190) (HR 1.38;
95% CI 1.09e1.76; P < 0.01 and HCT-CI 0 vs. 4 (n ¼ 38) (HR
2.82; 95% CI 1.95e2.50; P < 0.001. Further, multivariate an-
alyses identiﬁed arrhythmia, diabetes mellitus, cardiovas-
cular comorbidities, infection, hepatic comorbidities, and
renal comorbidities as signiﬁcant risk factors among the
HCT-CI variables. In univariate analyses, higher mEBMT was
associated with inferior OS in the comparison of mEBMT 0e3
Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107S90with 4e6 (HR 1.59; 95% CI 1.27e2.00; P < 0.001). HCT from a
female donor to a male recipient (FDMR) and disease status
were signiﬁcant risk factors among themEBMT variables. We
developed a new risk score (ATL-HCT-PI) based on known
risk factors (PS, human leukocyte antigen mismatch, ABO
mismatch), age (50, 51e62, 63 years), arrhythmia, dia-
betes mellitus, cardiovascular comorbidities, infection, he-
patic comorbidities, renal comorbidities, FDMR, and disease
status (CR vs. non-CR). ATL-HCT-PI scores were collapsed into
three risk groups: ATL-HCT-PI 0e7 (n¼ 285), 8e14 (n¼ 237),
and 15 (n ¼ 92), which statistically predicted 3-year OS
(48.3%, 29.2%, and 5.5%, respectively) (Figure). The better
predictive performance of ATL-HCT-PI for OS was
conﬁrmed using c-statistics (c-statistics: ATL-HCT-PI ¼
0.705, HCT-CI ¼ 0.592, and mEBMT ¼ 0.601).
Conclusions: ThenewlydevelopedATL-HCT-PI canbeauseful
tool for predicting mortality in HCT for patients with ATL.PEDIATRIC DISORDERS87
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Background: Patients with sickle cell disease (SCD) have an
average life expectancy of 39 years. The only known curative
therapy is allogeneic stem cell transplantation (AlloSCT) from
an HLA-matched donor (Talano/Cairo EJH, 2014). We have
demonstrated 100% EFS and absence of sickle cell symptoms
following reduced intensity conditioningandmatched sibling
bone marrow or cord blood AlloSCT (Bhatia/Cairo et al, BMT,
2014). However, matched sibling donors (MSD) and matched
unrelated donors (MUD) are limited and unrelated cord blood
transplant results are poor (Radhakrishnan K/Cairo et al.,
BBMT 2013, Kamani et al., BBMT, 2012). FHI TCD stem cell
transplantationhas beenusedwithhigh engraftment and low
aGVHD rates in high risk thalassemia patients and similar
resultswere reportedwith bothmalignant andnonmalignant
diseases (Sodani et al., Blood, 2010). Using a similar approach,
we reported the success of CD34 selectionwith T-cell addback
following MUD transplant in children (Geyer/Cairo BJH,
2012). FHI TCD AlloSCT could expand the donor pool and
improve outcomes for patients with high risk SCD.
Objective: To determine the safety and feasibility of FHI TCD
AlloSCT with T-cell addback in patients with high-risk SCD.
Methods: A multicenter consortium was developed to
investigate this approach (Fig. 1). Patients (2-<21 yrs) without
an 8/8 HLA MSD or MUD and who have 1 high-risk
SCD features are eligible. Patients receive hydroxyurea
(60mg/kg/d) and azathioprine (3mg/kg/d) day -59eday -11,
ﬂudarabine (30mg/m2/d x5d), busulfan (3.2mg/kg/d x4d),
thiotepa (10mg/kg x1d), cyclophosphamide (50mg/kg x4d),Haploidentical AlloSCT Sickle Cell Disease Consortium.
